Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together, we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit SyneosHealth.com.
Protech Pharmaservices Corporation (also known as PPC group) was found in 1997, provides professional services for clinical studies to pharmaceutical and biotechnology companies. Headquartered in Shanghai, China, PPC group offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 early phase trials, including innovative phase 1 pharmacokinetic, generic bioequivalence and biosimilar studies, to pharmaceuticals companies. In addition, PPC group has conducted over 400 innovative phase II-IV trials, covering all 24 therapeutic arenas. We have been audited more than 30 times by numerous regulatory authorities, including Japan PMDA, ANSM, NCPB , US FDA and China CFDA, etc. To fulfill harmonized bioequivalence standard for phase 1 clinical site, PPC group has set up a phase 1 center in Taipei McKay Memorial Hospital in 2012; and co-found a phase 1 center with Xuzhou medical hospital in early 2017. Combining the strengths of Xuzhou Medical University, PPC has established strong early phase drug development especially in the bioavailability and bioequivalence research field over the past two decades. Headquartered in Shanghai, PPC has professional focuses in clinical operations, phase 1 unit and clinical operations, data management, biostatistics and project management and bioanalytical laboratory. In addition, we have expertise in Taiwan and Korea which we also provide the services of clinical outsourcing services from phase I to phase IV.
BioDuro is a leading life sciences research organization that provides biopharmaceutical clients with comprehensive, integrated drug discovery services spanning from target identification through Phase III. With depth and breadth of therapeutic expertise in small molecule discovery, and large molecular development and scale up, combined with unique technology platforms, BioDuro is well positioned to help clients significantly accelerate their lead discovery programs.
With its headquarters located in Santiago, California, the company was established in Beijing in 2005. It opened its branches and drug discovery center in Shanghai in 2012. BioDuro’s global operations include a total of about 700 employees in Santiago, Beijing and Shangha. It has a 100,000 sf facility in Beijing, a 92,000 sf state of the art facility in Shanghai, and a team of highly experienced research staff and scientists, of whom 20% own Phd degree and 15% overseas background.
With the highest concentration of drug discovery expertise of any contract research organization (CRO) in China and a broad range of capabilities in chemistry, discovery biology, drug metabolism and pharmacokinetics (DMPK), pharmacology, as well as integrated preclinical research and development services, BioDuro brings superior insight and innovative solutions to its clients’ drug discovery programs. Through a strategic partnership with X-Chem Inc., BioDuro is able to conduct innovative hit and lead generation by using its proprietary DNA-based chemical libraries, giving the clients access to large, diverse libraries of compounds that can be used to better interrogate a broad range of high priority drug targets, which can significantly accelerate lead discovery and improve the probability of success.
Porton Pharma Solutions Ltd. (former name: Porton Fine Chemicals Ltd) founded in 2005, is a top-tier CDMO, providing services to the global pharmaceutical industry with intergraded research, development and manufacturing of custom drug intermediates and APIs.
We operate three Process R&D Centers, and three Manufacturing Sites across China, and leading US based CRO J-Star with expertise in GMP/GLP synthesis, Crystallization research and High potent handling etc.
Supported by >1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across China, North America and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and high-quality, cost-effective manufacture of APIs and/or drug intermediates.
Ask Us How We Can Help You @ www.porton.cn
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
Deep Intelligent Pharma is a newly founded start-up, aiming to use most advanced AI and blockchain technologies to empower and accelerate drug discovery and development. With our end-to-end AI-driven platform, we enable any pharmas to move compound(s) from lab to marketing in a most effective manner with great quality.
Atman is a leading language intelligence corporation that specialists in provides language technology solutions, including professional machine translation、medical machine writing、medical knowledge graph and artificial intelligence interaction. Headquartered in Beijing and subsidiaries in Suzhou, China.
Atman was founded by artificial intelligence scientists from Microsoft. Our core staff are highly professional, Most of them are coming from Microsoft Research Lab、IBM Watson、Baidu and France Telecom.
As an expert in providing reliable technology solutions & services for medical professionals, we have substantial experience to provide language technology solutions for our clients throughout the world.
Atman's core products and services are designed to increase efficiency, greatly shorten translation processing, reduce translation costs, accelerating the speed of innovation, closes the gap between the goals of your business and the technologies needed to get you there to deliver effective.
Atman is dedicated to supporting and developing translation software and services, and break down language barriers so you can flourish in complex global markets.
JenKem Technology is dedicated to the development and supply of PEG-based products and custom PEGylation services, with worldwide distribution, and the recent significant addition of new R&D through commercial scale GMP facilities.
Development and manufacture of a wide range of PEG derivatives with high purity and low polydispersity, currently in 1 gram to 40 kg or greater sized batches, under ISO 9001 and ISO 13485 certified Quality Management Systems, following ICH Q7A guidelines and operating under cGMP protocols for regulated customers.
Custom synthesis of Y-Shaped PEGs, Methoxy PEGs, Homobifunctional PEGs, Heterobifunctional PEGs, Multi-arm PEGs, Multi-arm Heterobifunctional PEGs, Monodisperse (Discrete) PEGs, Biodegradable PEG Co-Polymers (such as PEG-PLGA, PEG-PLA, PEG-PCL, and other block polymers), and PEG GPC Standards.
Custom PEGylation of proteins, peptides, oligonucleotides, and small molecules; and conjugation of PEGs to other polymer systems. Large scale manufacturing on a custom synthesis basis, which offers the flexibility to match a customer’s specifications.
CAS, a division of the American Chemical Society, is dedicated to the ACS vision of improving people's lives through the transforming power of chemistry. The CAS team of highly trained scientists identifies, aggregates, and organizes all publicly disclosed chemistry information, creating the world's most valuable collection of content that is vital to innovation worldwide. Scientific researchers, patent professionals and business leaders around the world rely on a suite of research solutions from CAS that enables discovery and facilitates workflows to fuel tomorrow’s innovation. Flagship solutions include SciFinder®, SciFindern, and STNextTM.
E3 was founded by a group of veterans from the pharmaceutical industry determined to solve the serious problems with laboratory safety and energy-efficiency.
The advent of E3's patented breakthrough innovations, the Bernoulli Laminar Air-Curtain Containment Hood and SmartFlow Damper System, has brought forth a solution for the age-long global dilemma of having to compromise between laboratory safety and energy efficiency.
The Bernoulli Hood delivers exceptional "zero-spill" containment safety performance while simultaneous providing unparalleled energy efficiency of up to 80%. With the Bernoulli Hood, laboratory owners can enjoy an unprecedented level of worker safety and HVAC energy cost reduction, drastically reducing their laboratory carbon footprint to achieve an unforeseen level of sustainability.
The Bernoulli SmartFlow Damper System is the most compact and simplified airflow control solution in the world. With an accuracy of over 95% and a response time of less than 2.5 seconds, it is also the first and only product to control airflow through direct real-time measurement of flowrate. Its integrated and patented multi-vane technology eliminates the complexities and costs associated with airflow testing, adjusting and balancing work.
FenXun Partners is a law firm established in Beijing and approved by the Beijing Justice Bureau in 2009. Our mission is to deliver services that help clients achieve their strategic and commercial objectives with precision. Beijing-based and globally experienced, our lawyers understand the commercial, operational and political realities that shape high-value transactions in China and draw upon their deep experience to provide practical advice.
Established in 2015, the Baker McKenzie FenXun (FTZ) Joint Operation is staffed by both locally admitted and foreign-licensed lawyers from Baker McKenzie and FenXun Partners, advising leading Chinese and multinational companies on both China domestic and cross-border issues across the full spectrum of corporate and commercial law.
AnJie Law Firm was founded by a group of senior lawyers committed to providing a high quality of service to international and domestic clients. Our attorneys are highly-regarded advisors with years of legal experience in a wide variety of fields, including insurance, intellectual property, antitrust, private equity, mergers & acquisitions, employment, TMT, capital markets, government policies, general corporate and regulatory matters, and high-stakes litigation and arbitration. Clients consistently give high marks to our services, acknowledging our attorneys’ effectiveness, reliability, and creativity. AnJie has quickly established its reputation as a first tier, elite law firm in China. Since its inception, AnJie Law Firm has been awarded “Rising Firm of the Year” (2013) by Asian Legal Business (ALB), and ranked within ALB’s list of “China’s Fastest 10 Growing Firms”. More recently, AnJie was awarded “Employer of Choice 2016” by ALB, “2016 Employer of Choice Career Outlook China: PRC Firm” by LEGALBAND and “2016 Fast 10 Growing Law Firms in China”, again by ALB. In addition, AnJie has been recognized both as a “Recommended Leading Firm”, and “Firm of the Year” in major practice areas including Antitrust/Competition, M&A, Arbitration & Litigation, and Intellectual Property, by Chambers & Partners, ALB, Asialaw, Legal 500 and other renowned ranking institutions.
Headquartered in Beijing, we have opened branch offices in Shanghai and Shenzhen, and continue to growing rapidly, with more than 300 professionals and supporting staff currently working across our three offices. As successful practitioners in their fields, our lawyers continue to demonstrate excellence in their legal work and commitment to their profession. Most of our lawyers have practiced in leading international law firms and gained many years of experience before joining AnJie. Certain of them have worked in national ministries of the People’s Republic of China and in international organizations, and have built their careers while maintaining harmonious connections with various government bodies and international organizations.
Shanghai Beshining Law Office was founded in 2013 by main partner Xue Qi and his team from Shanghai Zhixin Patent Agent Ltd., and its headquarters is located in Shanghai.
As one of the few leading law offices authorized to engage in patent and trademark, we currently house more than one hundred personnel including lawyers, patent attorneys, and other legal and technical professionals with diverse background and expertise.
Our partners and their team have been providing nearly thousands of domestic and foreign enterprises with full intellectual property legal service and comprehensive domestic and foreign legal service of patent, trademark, copyright, integrated circuit layout design, anti-unfair competition and trade secret. The quantities of patent applications, trademark applications and lawsuits are all top rated nationwide. Especially, our team in Chemistry, Pharmaceuticals and Biology in which we have 16 lawyers and 36 patent attorneys is in the top tier of China, and our firm enjoys a patent grant rate of over 90% for invention in such areas. For three consecutive years (2015-2017), our team was awarded the title of Outstanding IP Service Team in China by China IP Magazine and China Daily IPR Channel.
LexOrbis is one of the most recommended full service IP firms in India with offices at 3 locations namely, New Delhi, Mumbai and Bangalore. We have a strong team of over 65 attorneys including 46 patent attorneys having expertise in the field of mechanical, electronics, wireless communication, software, mobile applications, chemistry, biotechnology, etc. who are involved in drafting new patent applications originating from India and filing and prosecuting international patent applications. A team of over 19 lawyers at our firm also have deep expertise in handling trademark prosecution and contentious cases. Our patent and trademark attorneys work in combination with our IP litigators to handle a large number contentious IP cases such as pre-and post- grant oppositions, cancellation and infringement suits and criminal enforcement of India rights in India.
Founded in 2011, we provide small molecule process development and manufacturing services to the pharmaceutical industry.
We evaluate our clients needs and provide creative solutions to deliver valuable, enabling compounds from small quantities of unique compounds to support early and pre-clinical development, to large volumes of key intermediates for clinical studies and commercial supply. In addition to all the chemistries you would expect from a world class small molecule developer, we have specialized expertise in developing chiral compounds, unnatural amino acids, and sulphur containing molecules.
Raffles operates 40,000 sq. ft of modern, well-equipped facilities across two sites in Guangdong, and a business development and technical support function in Philadelphia.
Beijing HFK Bioscience Co. Ltd. (HFK) was founded in 2008 in conjunction with theInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, in Changping District, Beijing, China. HFK is dedicated to developing and providing laboratory animals, animal models for human diseases,laboratory animal diets and related services.HFK's success results from its large group of experienced researchers and innovative elite with its high emphasis on quality. The quality of its products and services is beijing maintained by this large and dedicated research group and consultant team comprised
by international and domestic experts in the field of laboratory animal science. HFK consists of four branches: the Laboratory Animal Resources (LAR), the Laboratory Animal Diets (LAD), the Research and Development (R&D) and Quality Assurance Unit(QAU).
◆The LAR provides more than 1,000,000 SPF rodents annually, including 200 strains of spontaneous and genetically engineered animal models for human diseases.
◆The LAD owns an automated manufacturing system with the capability to produce 5,000 tons of a wide array of high quality diets per year, including specialformulated diets for all kinds of laboratory animal. All diets are in compliance with GLP standards.
◆The R&D offers the service for generating animal models for human diseases,including the surgical, chemical or diet induced, transgenic, gene knock-in or gene knock-out animal models. Cryopreservation and cryorecovery services are alsoavailable.
◆The QAU is independent of other branches, with advanced equipments and a well trained team. The unit is responsible for running the ISO9001 quality management system of the company.
We look forward to working with you to provide you with your basic research needs. We are dedicated to provide you the utmost in quality and price.
China Medical City (Taizhou National Medical High-tech Zone) is located in Taizhou City, Jiangsu Province. As the first national level life science hi-tech Park, China Medical City (CMC) is jointly built by Ministry of Science and Technology, China Food and Drug Administration (CFDA), National Health and Family Planning Commission, China Administration of Traditional Chinese Medicine and Jiangsu Provincial Government. Jiangsu CFDA CMC Branch, Jiangsu Food and Drug Inspection Institute CMC Branch, Jiangsu Medical Device Testing Center CMC Branch have been established successively to better support the industry and offer services to the companies more efficiently.
We are committed to building the largest life scienceindustrial base with the most integrated industrial chainin China. China Medical City has cooperated with over 50 famous life science R&D institutes domestic and abroad, and there are over 900 companies including AstraZeneca, Boehringer Ingelheim, Nestle, Sanofi-Pasteur, and Takeda in China Medical City.
China Medical City, a new city for life science industryin China, your first choice for investment!